Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia - Full Text View

Sponsored by:	Sangart
Information provided by:	Sangart
ClinicalTrials.gov Identifier:	NCT00633659

Purpose

The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.

Condition	Intervention	Phase
Vascular Disease Chronic Critical Lower Limb Ischemia	Drug: Hemospan® Drug: Voluven®	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Subject), Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia

Resource links provided by NLM:

MedlinePlus related topics: Foot Health Vascular Diseases

U.S. FDA Resources

Further study details as provided by Sangart:

Primary Outcome Measures:

To investigate the effect of Hemospan on vascular resistance by evaluating blood flow in the forearm [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To evaluate the effects of Hemospan on local skin blood flow and tissue oxygenation in an ischemic region of the foot [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Enrollment:	6
Study Start Date:	September 2007
Study Completion Date:	December 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Cohort 1: Experimental 250 mL of Hemospan (N = 4); or Voluven (N = 2)	Drug: Hemospan® 4.3 g/dL MalPEG-Hb in Lactated-Ringers solution Drug: Voluven® 6% hydroxyethyl starch solution in 0.9% saline
Cohort 2: Experimental 500 mL of either Hemospan (N = 4); or Voluven (N = 2)	Drug: Hemospan® 4.3 g/dL MalPEG-Hb in Lactated-Ringers solution Drug: Voluven® 6% hydroxyethyl starch solution in 0.9% saline

Detailed Description:

Hemospan® is a novel hemoglobin-based oxygen carrier developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. Because of its molecular size and oxygen binding characteristics, Hemospan selectively off-loads oxygen in tissues predisposed to low oxygen tension. Preclinical evidence suggests that Hemospan provides volume expansion and enhances tissue perfusion. Hemospan is therefore being developed as an oxygen-carrying plasma expander for patients where tissues are at risk of inadequate perfusion and oxygenation.

In patients with chronic critical lower limb ischemia (CCLI), the primary cause of ischemic symptoms in the leg is insufficient perfusion. As many of the patients suffering from CCLI are elderly and have concomitant disease, surgical procedures may not always be possible. The goal of all treatments is to improve the blood flow in the nutritional vessels of the ischemic areas; one such possibility may be to use an oxygen-carrying plasma expander.

Hemospan has been shown to improve the oxygenation of tissues by preserving functional capillary density. In addition, Hemospan has a high affinity for oxygen - a feature that is specifically designed to target the unloading of oxygen in the microcirculation where local PO2 levels are much lower (e.g., in ischemic regions).

Since Hemospan is a cell-free oxygen carrier, it should be able to perfuse capillaries that are so constricted that red blood cells are unable to flow through them.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adult male or female (surgically sterile or post-menopausal) patients with CCLI that meet the following definition: i) History of pain at rest and/or ulceration; ii) Ankle systolic BP/Brachial systolic BP Index (ABI) <0.6 at the time of inclusion; iii) Ankle systolic BP <70 mmHg and/or toe systolic BP <50 mmHg
Has received written and verbal information about the investigational product and the protocol by the investigator and has had the opportunity to ask questions about the study
Patients must sign an Informed Consent Form (ICF), that has been reviewed and approved by the independent Ethics Committee (EC)

Exclusion Criteria:

Severe congestive heart failure (EF <40%, or New York Heart Association Class III or IV
Any acute or chronic condition that will limit the patient's ability to complete the study
Recent acute coronary syndrome (unstable angina or myocardial infarction [MI] within 1 month)
Severe dementia or clinically significant psychiatric disorder requiring active treatment
Evidence of untreated or uncontrolled hypertension (SBP >180 mmHg, or DBP >100 mmHg), or a difference in systolic BP in each arm that is >15 mmHg (measured by cuff and a pen-Doppler at screening in the supine position, in both arms)
Smoking or use of any nicotine-containing product (e.g., snuff) within previous 24 hours before start of study
Any systemic rheumatic disease
Taking oral steroid therapy (does not include steroids taken intermittently via inhaler)
Chronic hepatic disease (abnormal LFTs >3X upper limit of normal, known history of Hepatitis C or B)
Chronic renal disease (creatinine >1.8 mg/dL, or known polycystic kidney disease)
Expectation of poor patient compliance with study protocol
Patients scheduled for surgical procedure within 7 days from start of this study
Involved in any investigational drug or device trial within 30 days prior to this study
Professional or ancillary personnel involved with this study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00633659

Locations

Sweden
Karolinska Universitetssjukhuset
Stockholm, Sweden

Sponsors and Collaborators

Sangart

Investigators

Study Director:

Robert M. Winslow, MD

Sangart, Inc.

More Information

Additional Information:

For more information about Sangart, Inc. This link exits the ClinicalTrials.gov site

Publications:

Bjorkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005 Apr;90(4):505-15.

Olofsson C, Ahl T, Johansson T, Larsson S, Nellgard P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006 Dec;105(6):1153-63.

Olofsson C, Nygårds EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow RM. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan((R))) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med. 2008 Feb;18(1):28-39.

Winslow RM. Red cell substitutes. Semin Hematol. 2007 Jan;44(1):51-9.

Responsible Party:	Sangart, Inc. ( Robert M. Winslow, M.D., Medical Director )
Study ID Numbers:	Sangart 6034
Study First Received:	March 4, 2008
Last Updated:	January 7, 2009
ClinicalTrials.gov Identifier:	NCT00633659 History of Changes
Health Authority:	Sweden: Medical Products Agency

Keywords provided by Sangart:

Hemospan
Oxygen carriers
Blood substitutes
Ischemia
Tissue oxygenation

Study placed in the following topic categories:

Vascular Diseases
Hetastarch
Ischemia

Additional relevant MeSH terms:

Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Ischemia

ClinicalTrials.gov processed this record on September 10, 2009